Instructions for Amaryl M (Glimepiride, Metformin) 30 pills
English product name
Amaryl® M
Release form
tabbed film coating, 2 mg+500 mg: 30 pcs
Description Amaryl M:
The tablets are covered with a white film sheath, oval, double-convex, with "HD25" engraved on one side and a risk on the other.
1 tab.
glymepiride micronized 2 mg
metformin hydrochloride 500 mg
Auxiliary substances: lactose monohydrate, sodium carboxymethylstarch, C30 povidone, cellulose microcrystalline, crospovidone, magnesium stearate.
Film sheath composition: Hypromellose, macrogol 6000, titanium dioxide (E171), wax Carnauba.
10 pcs - blister packs (3) - cardboard packs.
ATC codes
A10BD02 Metformin in combination with sulfonyl urea derivatives
Clinical-pharmacological groups / Group affiliation
Oral hypoglycemic preparation
Active substance
- metformin hydrochloride
- glymepiride micronized
Pharmacotherapy group Amaryl M:
Hypoglycemic oral combined agent (sulfonyl urea-biguanide derivative)
Testimony Amaryl M:
- Type 2 diabetes treatment (in addition to diet,
- exercise and body weight loss):
- when glycemic control cannot be achieved by monotherapy with glymepiride or metformin;
- when combined therapy is substituted with glymepiride and metformin,
- one combined preparation containing glymepiride and metformin is administered in a corresponding fixed combination.
Method of use, course and dosage Amaryl M:
Typically, the dose is determined by the target glucose concentration in the patient's blood. The lowest dose sufficient to achieve the necessary metabolic control should be applied.
During treatment it is necessary to regularly determine the blood glucose concentration. In addition, regular monitoring of the percentage of glycosylated hemoglobin in the blood is recommended.
Pharmacological effect:
Combined hypoglycemic agent.
Glymepirid is a hypoglycemic oral preparation derived from sulfonyl urea of the 3rd generation. It stimulates the secretion and release of insulin from pancreatic β cells (pancreatic action), improves the sensitivity of peripheral tissues (muscle and fat) to the action of endogenous insulin (extrapancreatic action). Sulfonyl urea derivatives increase insulin secretion by closing ATP-dependent potassium channels located in the cytoplasmic membrane of pancreatic β cells. By closing potassium channels, they depolarize β cells, which opens calcium channels and increases the flow of calcium into the cells.